Icariin Improves Metabolic Response to Exercise by Promoting TFEB-Dependent Mitochondrial Clearance and Metabolic Reprogramming in C57BL/6 Mice and C2C12 Myotubes

Why It Matters

Icariin’s activation of the TFEB‑mitophagy axis provides a novel, targetable pathway to boost exercise efficiency and combat fatigue, opening avenues for nutraceutical and therapeutic strategies in sports and metabolic health.

Key Takeaways

• Icariin (50‑100 mg/kg) boosted VO₂ max and endurance in mice.
• Treated mice showed lower post‑exercise lactate and larger oxidative fibers.
• Icariin shifted C2C12 metabolism to oxidative phosphorylation, reducing lactate output.
• RNA‑seq showed mitophagy genes up‑regulated via TFEB dephosphorylation and nuclear entry.
• Silencing TFEB blocked Icariin‑induced mitophagy, lactate reduction, and performance gains.

Pulse Analysis

Icariin, a prenylated flavonoid from Epimedium, has long intrigued researchers for its ergogenic potential. While earlier animal work linked the compound to longer swimming times and stronger load‑bearing capacity, the molecular underpinnings remained speculative. The latest study bridges that gap by demonstrating that oral Icariin not only elevates VO₂ max and endurance in mice but also triggers a cascade of cellular events that remodel muscle metabolism at the mitochondrial level. This positions Icariin alongside other natural products that influence performance, yet distinguishes it through a clear mechanistic pathway.

At the cellular core of Icariin’s effect is the transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy. The research shows that Icariin induces TFEB dephosphorylation, prompting its migration into the nucleus where it activates a suite of mitophagy genes. Enhanced mitophagic flux clears damaged mitochondria, preserving a high‑quality mitochondrial network that favors oxidative phosphorylation over glycolysis. Consequently, lactate production drops, and muscle fibers transition toward an oxidative phenotype, directly translating into improved fatigue resistance and contractile force. The TFEB dependency was confirmed by siRNA knockdown, which erased all metabolic and performance gains.

These findings have practical implications for athletes, aging populations, and patients with metabolic disorders where mitochondrial dysfunction drives fatigue. By targeting TFEB, Icariin could complement training regimens or serve as a therapeutic adjunct for conditions such as sarcopenia or chronic fatigue syndrome. Future work should validate the pathway in human trials and explore synergistic combos with established endurance enhancers. If translatable, Icariin may become a cornerstone of next‑generation nutraceuticals aimed at optimizing mitochondrial health and exercise performance.